Privacy Policy
Signals Blog

Contributors

Categories

Update from the Clinic: August

by | Sep 29, 2015

. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is...

The tiny fingers that touch stem cells

by | Sep 22, 2015

. I was reading Nature the other day and came across a neat article from Yukikio Yamashita’s group at the University of Michigan entitled Nanotubes mediate niche–stem-cell signalling in the Drosophila testis. It may not sound interesting to our average reader, but the...

The waiting game: First human iPSC clinical trial on hold

by | Sep 1, 2015

. Nicole Forgione is a post-doctoral fellow working in the Fehlings group at the Toronto Western Research Institute. Currently she holds a Toronto Western Research Institute Fellowship to support her work on cell-based regenerative therapies for traumatic spinal cord...

Update from the Clinic: July

by | Aug 25, 2015

. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...

Cell Therapy Deal Review: July

by | Aug 18, 2015

. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...